Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2006

View Archived Issues

DHEA beneficial for long-term morphine use

Ralfinamide blocks chronic pain behavior and underlying neural ectopic activity

Snapshots on antidiabetic drug candidates in clinical development

Polyphenolic extract from red grapes beneficial for metabolic syndrome

Nymox reports promising phase II with NX-1207 for BPH

NovaCal and Alcon enter licensing agreement for nonantibiotic antiinfective compounds

Preclinical studies of Novavax intranasal flu vaccines begin

Wyeth presents novel Kv channel disinactivator, with efficacy in a seizure model

ABT-888: A PARP inhibitor in a phase 0 trial at NCI

Merck & Co. reveals new Chk1 inhibitors

Schering-Plough presents new lead BACE1 inhibitor

Pepscan equity investment supports progress in R&D pipeline

AnorMED broadens scope of Poniard's picoplatin license

Pharmacopeia advances Organon's lead compounds

Rigel receives milestone payment from Serono

Nastech's intranasal insulin begins phase I clinical evaluation

Early clinical trials begin with sanofi-pasteur's H7N1 pandemic vaccine

Seaside Therapeutics awarded Autism Speaks grant

pSivida initiates phase II trial of mifepristone eye drops for IOP

Frova for menstrual migraine prevention accepted for filing in U.S.

Alexion seeks U.S. approval for treatment of rare genetic blood disorder

Idenix receives first approval for novel CHB treatment

Recent patents describe new treatment options for endocrine-related disorders

New agents for treating blood coagulation disorders reported in recent patents

Recent patents disclose novel treatment strategies for HCV infection

Novel long-acting form of BNP shows potential for cardiovascular and renal disorders

Novel leukotriene A4 hydrolase inhibitors reported by deCODE

New CCR5 antagonists to treat HIV infection prepared and tested at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.